| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8785427 | Brachytherapy | 2017 | 7 Pages |
Abstract
For high-risk prostate cancer treated with combination HDR brachytherapy and EBRT, mpMRI evidence of SVI predicted for biochemical failure, whereas traditional pretreatment variables did not. Therefore, pretreatment 3T mpMRI appears useful for identifying men who may benefit from treatment intensification.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
John V. Hegde, D. Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Steven S. Raman, Nicholas G. Nickols, Christopher R. King, Amar U. Kishan, Michael L. Steinberg, Mitchell Kamrava,